Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol
Internal Medicine Department, Hospital Vega Baja, 03314 Orihuela, Spain
Silvia Roure
Infectious Diseases Department, North Metropolitan International Health Unit, Germans Trias i Pujol University Hospital, PROSICS North Metropolitan, 08916 Badalona, Spain
Marta Arsuaga
Tropical Medicine Unit, Infectious Diseases Department, La Paz-Carlos III University Hospital, 28046 Madrid, Spain
Asunción Pérez-Jacoiste
Internal Medicine Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
Magdalena García-Rodríguez
Infectious Diseases Department, Hospital General Universitario de Valencia, 46014 Valencia, Spain
José A. Pérez-Molina
National Referral Unit for Tropical Diseases, Infectious Diseases Department, Hospital Ramón y Cajal, IRYCIS, 28034 Madrid, Spain
Dora Buonfrate
Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, 37024 Verona, Italy
José María Saugar
Parasitology Department, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28222 Madrid, Spain
Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.
